GAO’s reports and testimonies give Congress, federal agencies, and the public timely, fact-based, non-partisan information that can improve government operations and save taxpayers billions of dollars.
People from various racial and ethnic groups may experience health disparities—preventable differences in health outcomes. Discrimination, economic instability, and lack of health care access are some of the factors that can contribute to these disparities.
If you were near a person who later tests positive for an infectious disease, an exposure notification app can let you know. These apps allow for more rapid and broader contact tracing—ideally helping to slow disease spread.
About half of the U.S.
While COVID-19 cases have declined in recent months, the U.S. is still experiencing serious economic and public health repercussions due to the pandemic. In our 7th comprehensive report, we found more ways to improve federal programs related to the pandemic and other future emergencies.
COVID-19 has had a disproportionate impact on the 1.4 million residents who live in nursing homes in the U.S.
We looked at the frequency and duration of COVID-19 outbreaks in nursing homes from May 2020 through January 2021.
How has the need for and availability of services for mental health and substance use disorders changed during the COVID-19 pandemic?
Evidence suggests these conditions increased while access to care decreased.
Pour la version française de cette page, voir GAO-21-484.
USAID and CDC have invested in global health security, helping other countries build capacity to handle infectious diseases. In the 5 years before COVID-19, the agencies spent about $1 billion in over 30 countries.
Remdesivir was the first drug approved by the Food and Drug Administration to treat COVID-19. Gilead Sciences, Inc., originally developed it to treat other viral diseases.
We reviewed federal contributions to development of remdesivir and related agency patent rights.
As of Dec.